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378that each person’s risk was estimated using a statistical model
(within-person variability). Said differently, Ford (1) treats each
person’s risk as if it were observed without substantial error, which
is true for age, blood pressure, and cholesterol but not the case for
Framingham risk functions. Thus, the standard errors Ford reports
for 10-year risks of CHD and CVD are systematically under-
estimated. Ford (1) does not discuss this. Moreover, the method
used for evaluating trends does not seem to incorporate uncertainty
in risk estimates.
What are the implications of this statistical issue for how clini-
cians, researchers, and policymakers should interpret Ford’s study
(1)? The implications may be negligible for readers interested
strictly in average population risk and uninterested in trends.
However, if the reader is interested in trends, Ford’s results (1) are
more difﬁcult to interpret, especially in African Americans,
Mexican Americans, women, and individuals whose age falls be-
tween 30 and 39 years old or 40 and 49 years old. Each of these
groups have p values at the borderline of signiﬁcance, at the 5% or
10% level in some of Ford’s (1) analyses. Would incorporation of
the uncertainty in 10-year risks of CHD and CVD have affected
whether these or other comparisons demonstrated a trend? With
the information we have, we cannot tell.
Methods such as bootstrap analysis (4) and the Taylor series-
based delta method (5) have been used to capture uncertainty
and approximate variance when a closed form estimate is intrac-
table, particularly in decision analysis and cost-effectiveness anal-
ysis (6). With adequate information, these methods could be
applied to analyses like Ford’s (1). In their absence, we believe it is
important for readers to recognize that analytics incorporating
Framingham CHD or CVD risk scores do not reﬂect the within-
person uncertainty in risk.*Joseph A. Ladapo, MD, PhD
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Suggestions to Increase Diagnostic
Accuracy
A very interesting article was recently published on the role of
18F-labeled ﬂuorodeoxyglucose positron emission tomography/
computed tomography ([18F]FDG-PET/CT) for diagnosis of
prosthetic valve endocarditis (PVE) (1). Although [18F]FDG-
PET/CT alone could not actually be considered the “magic” mo-
dality capable of diagnosing any PVE episodes, in light of
the results of the present study, it could certainly be considered
one more weapon in the diagnostic arsenal for PVE detection.
In particular, some remarks and considerations could be sug-
gested to increase the diagnostic accuracy of [18F]FDG -PET/CT:
in this difﬁcult clinical and diagnostic setting, the preparation of
the patient and the image acquisition protocol have fundamental
roles. Beyond the factors already cited by the authors, such as a diet
rich in fat and very low in carbohydrate to minimize myocardial
[18F]FDG uptake and the opportunity to perform [18F]FDG-
PET/CT before the start of antibiotic therapy (metabolic changes
occur very early and precede morphological ones), other factors
could be crucial in diagnosing PVE and should be addressed:
acquisition time after [18F]FDG injection, timing of prosthetic
valve positioning, and blood glucose levels in the cardiac setting.
All the studies conducted so far have adopted the “standard”
PET/CT protocol used for oncological purposes, consisting
of imaging acquisition performed 1 h after [18F]FDG injection.
Because valve infective foci can be very small around the spatial
resolution of PET systems (4 to 5 mm) and because cardiac uptake
is still present despite adequate dietary preparation, low blood
glucose levels and delayed imaging could improve sensitivity (2).
Hyperglycemia is widely known to be able to lower the sensitivity
of [18F]FDG-PET/CT because [18F]FDG is a glucose analog
and its uptake in malignant and inﬂammatory cells is affected by the
blood glucose level acting as a competitor. Consequently, the use-
fulness of [18F]FDG-PET/CT in patients with hyperglycemia could
be limited (3,4); for example, a glucose level of 1.8 g/l could be
different in terms of [18F]FDG uptake interference from 0.8 g/l,
especially in relation to the small dimensions of the area of interest.
Despite the suggestion by Rabkin et al. (5) that high blood glucose
levels did not signiﬁcantly affect the detectability rate of infectious
and inﬂammatory processes (although endocarditis was not
considered) and had no statistically signiﬁcant impact on the number
of false-negative studies, we must consider the synergistic effects
among blood glucose levels, dimensions of the structure or lesions to
be studied, and the “cardiac setting.” In fact, another element
affecting the accuracy and impairing detectability is the constant
movement of the entire heart, the entire mediastinum, and the entire
thorax, causing motion artifacts and a “smearing effect.” The solu-
tions to, or at least ways to reduce, these problems could be the use of
ß-blockade and cardiac gating to attenuate cardiac motion and ar-
tifacts (6).Moreover, it could be reasonably hypothesized that higher
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379sensitivity could be achieved with delayed scanning, providing a
better target-to-background contrast due to the clearance of the
background and blood-pooling activity. [18F]FDG uptake by acti-
vated monocytes/macrophages in PVE may increase up to 2 to 3 h,
and delayed imaging performed 2 to 3 h after [18F]FDG injection,
which obviously requires a longer acquisition time, could be
considered in patients with a negative 1-h scan (2).
Another critical issue is the timing of prosthetic valve posi-
tioning, because a functional uptake could persist for more than 1
month after intervention, despite the time necessary to reach a
complete disappearance of [18F]FDG uptake after intervention,
and is extremely variable from case to case and depends on many
factors including age, clinical status, and cardiologic condition of
the patient; therefore, a longer cutoff for scheduling the study
would be desirable before performing [18F]FDG-PET/CT (7).
We are aware that all the above-mentioned suggestions and pro-
posals are not established or validated and are far from being “evi-
dence-based” medicine; therefore, legitimately, many doubts about
their effectiveness may arise. However, as Saby et al. (1) have effec-
tively addressed an unexplored issue, in the same manner, a more
rigid and complete protocol could be considered for future pilot
studies of this topic, conﬁrming or controverting these insights,
which derive more from daily practice than from evidence-based
results. Finally, evidence-based results can only derive from contin-
uous and numerous attempts to conﬁrm or controvert hypotheses,
especially in a challenging clinical diagnostic scenario like this.*Francesco Bertagna, MD
Raffaele Giubbini, MD
Giorgio Treglia, MD*Nuclear Medicine
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